FDA Investigator Anthony E Keller, RPh

Anthony E Keller, RPh has conducted inspections on 195 sites in 21 countries as of 22 Sep 2014. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
195
Last Inspection Date:
22 Sep 2014
Investigator Role:
FDA Investigator
Redica ID:
100000905
Countries of Inspections:
Belgium, United Kingdom of Great Britain and Northern Ireland, United States of America, Canada, Norway, Ukraine, Russian Federation, India, Germany, Croatia, Poland, Romania, Italy, Brazil, Singapore, Denmark, France, South Africa, Hungary, Colombia, Thailand
FDA Investigators that have inspected at least one site in common with Anthony E Keller, RPh:
Alanna L Mussawwir Bias, Allen F Hall, Amanda E Lewin, PhD, Amber Smith, Angel K Sandhu, Angela Shepas, Anh M Lac, Art O Czabaniuk, Ashar P Parikh, Azza Talaat, Barbara T Carmichael, Celeta S Coves, Charles D Brown, Christina N Maurino, Courtney N Long, Daniel J Roberts, Daniel L Aisen, Darin S Wiegers, David A Lum, David G Eng, Deborah K Richardson, Deborah Kleinfeld, Denise L Burosh, Dennis M Farley, Doan T Nguyen, PharmD, Dr. Sriram Subramaniam, PhD, Edward D Harris, Edward D Mcdonald, Emily B Camire, Eric E Joneson, Estefania Fernandez, Gary L Zaharek, Gavin T Cua, Geoffrey M Leist, George C Amedro, Gerald N Mcgirl, DDS, Helen J Hamaoka, Herbert E Arden, Hugh M Mcclure, II, Humberto Z Gomez, James E Frye, James M Kewley, Jane M Kreis, Janet Pulver, Janete F Guardia, Janice R Small, Jason Markwardt, Jazmine M Welcher, Jeffrey M Watson, Jennifer S King, Jessica B Clark, Jessica B Zachman, Joan T Briones, Joel D Martinez, John A Iwen, Joy P Matthias, Karen D Phung, Karen J Bak, Karen L Kosar, Karla J Gibler, Kathleen B Swat, Kathryn A Krentz, Kay M Vialpando, Kellia N Hicks, Kenneth Zemman, Kirtida Patel, Kristin M Abaonza, Lance Mde Souza, MBA, Lauren E Swantko, Laverne Puckett, LCDR Jennifer H Rhyu, Lesley A Swanson, Levering Keely, BSN, MPA, Lili M Carr, Lori J Silverstein, Mabel M Lee, Makini Cobourne Duval, PhD, Maridali Deleon Torres, Marie K Kinkade, Marion W Nadeau, Mary Ewilkerson Brinsko, Mary T Carden, Matthew A Johnson, Matthew C Watson, Melissa D Kalik, Miah I Schneider, Miaja Umaedi, Michael F Skelly, PhD, Michael S Araneta, Mike M Rashti, Min Shanmabel Liu, Minh D Phan, Mohsen Rajabi Abhari, FDA, Nancy A Bellamy, Nayan J Patel, Neal D Singletary, PhD, Nympha V Florendo, Patrick D Stone, MS, Patrick E Gainer, Paula J Bretz, Rachel J Cantrell, Rebecca T Davis, Renee L Rice, PhD, Richard L Bartlett, Robles, Roger D Gawne, Ruben C Ayala, PharmD, Sam H Haidar, PhD, Sandra S Saniga, Scott B Laufenberg, Shelley H Beausoleil, Shelley H Roberts, Sherri J Jackson, Sherri N Rohlf, MD, Sripal R Mada, PhD, Stephanie A Slater, MS, Stephanie Mangigian, MS/OSH, RN, Stuart W Russell, Sunitha K Rajaram, PhD, Susan D Yuscius, Susanne M Richardson, MS RAC, Suzie L Kent, Tania Y Hall, Tara K Carmody, Thea C Grome, Thomas W Gordon, Timothy C Grome, Timothy T Kapsala, Vickie J Kanion, Vilmary Negron Rodriguez, William F Lagud, Jr, William J Foust, William P Tonkins, William V Millar, Xikui Chen (nmi), PhD

Anthony E Keller, RPh's Documents

Publish Date Document Type Title
January, 2012 EIR Prof Valery Bitenskyy, MD, PhD, ScD - EIR, 2012-01-30
July, 2003 FDA 483 Response Biomat USA, Inc. - Form 483R, 2003-08-04
June, 2000 FDA 483 Sheldon J Freedman, Ltd. - Form 483, 2000-06-22
September, 2003 EIR Private Label Packaging - EIR, 2003-09-16
January, 2013 FDA 483 Jerzy Windyga, MD, PhD - Form 483, 2013-01-18
April, 2010 FDA 483 Mark Glazebrook, MD, PhD - Form 483, 2010-04-09
January, 2013 FDA 483 Prof. Aleksander B Skotnicki - Form 483, 2013-01-11
October, 2012 FDA 483 Response Charles B Bernick, MD - Form 483R, 2012-12-11
January, 2012 EIR Prof Lyudmyla Dzyak - EIR, 2012-01-25
January, 2013 EIR Oleksandra Stasyshyn, MD, PhD - EIR, 2013-01-25
March, 2010 FDA 483 Jonathan Bernstein, M.d. - Form 483, 2010-03-05
May, 2003 FDA 483 Richard Briggs, MD - Form 483, 2003-05-21
November, 2003 EIR Siems Advanced Lasik Center Investigational Review Board - EIR, 2003-11-26
July, 2003 FDA 483 Biomat USA, Inc. - Form 483, 2003-07-18
May, 2013 EIR Onyx Pharmaceuticals, Inc., a Subsidiary of Amgen, Inc. - EIR, 2013-05-17
April, 2014 EIR Parexel Bionanalytical Services Division - EIR, 2014-04-04
May, 2003 EIR Richard Briggs, MD - EIR, 2003-05-21
January, 2013 FDA 483 Oleksandra Stasyshyn, MD, PhD - Form 483, 2013-01-25
June, 2000 EIR Freedman, Sheldon J, MD, FACS - EIR, 2000-06-22
February, 2011 FDA 483 Clinical Research Advantage, Inc - Form 483, 2011-02-10
May, 2013 FDA 483 Onyx Pharmaceuticals, Inc., a Subsidiary of Amgen, Inc. - Form 483, 2013-05-17
May, 2004 EIR Snyder, James MD - EIR, 2004-05-27
April, 2012 FDA 483 Douglas Lorenz - Form 483, 2012-04-25
March, 2010 FDA 483 Basic Food Flavors, Inc. - Form 483, 2010-03-04
August, 2003 FDA 483 Talecris Plasma Resources, Inc. - Form 483, 2003-08-21
April, 2013 FDA 483 Vivus, Inc. - Form 483, 2013-04-26
March, 2000 FDA 483 Matrix Biokinetics, Inc - Form 483, 2000-03-27
April, 2008 FDA 483 Eugene Shmelev, MD - Form 483, 2008-04-04
July, 2003 EIR Biomat USA, Inc. - EIR, 2003-07-18
November, 2003 FDA 483 Response Siems, Jon L., M.D. - Form 483R, 2004-04-22
May, 2014 FDA 483 Prof. Punnee Pitisuttihum (Mahidol University) - Form 483, 2014-05-23
November, 2003 EIR Siems, Jon L., M.D. - EIR, 2003-11-18
August, 2003 EIR Octapharma Plasma, Inc. - EIR, 2003-08-04
January, 2012 EIR Volodymyr Lebedynets, MD - EIR, 2012-01-18
February, 2012 FDA 483 Janos Takacs, MD, PhD - Form 483, 2012-02-08
March, 2010 EIR Basic Food Flavors, Inc. - EIR, 2010-03-04
May, 2014 EIR Lilly Nus Centre for Clinical Pharmacology - EIR, 2014-05-30
October, 2012 FDA 483 Charles B Bernick, MD - Form 483, 2012-10-30
November, 2003 FDA 483 Siems, Jon L., M.D. - Form 483, 2003-11-18
April, 2012 EIR Douglas Lorenz - EIR, 2012-04-25
January, 2013 EIR Jerzy Windyga, MD, PhD - EIR, 2013-01-18
August, 2003 FDA 483 Octapharma Plasma, Inc. - Form 483, 2003-08-04
May, 2004 FDA 483 Snyder, James MD - Form 483, 2004-05-27

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more